A bibliometric analysis of research on the mitochondrial roles in prostate cancer and the virtual design of LONP1 - specific antibodies using the GeoBiologics platform

BackgroundProstate cancer remains one of the most prevalent malignancies among men globally, with its incidence showing an upward trend worldwide. Mitochondria, as central regulators of cellular energy metabolism, play crucial roles in prostate cancer initiation, progression, and drug resistance mechanisms. While mitochondria-targeted therapeutic strategies have emerged as a significant focus in cancer research in recent years, comprehensive bibliometric analyses mapping the evolving landscape of this field remain scarce. This study systematically investigates research trends in mitochondrial-prostate cancer interactions through bibliometric methods, identifying LONP1 as an emerging research focus in mitochondria-related prostate cancer therapy. Building on these findings, we employed artificial intelligence to virtually design a LONP1-specific antibody, proposing novel therapeutic targeting strategies for this field. MethodsUtilizing the Web of Science Core Collection database (2015-2023), we conducted visualization analyses through CiteSpace and VOSviewer to map network relationships among countries, institutions, journals, authors, and keywords. Building on this foundation, a humanized antibody targeting LONP1 was computationally designed and screened through the GeoBiologics platform. ResultsAnalysis of 452 included publications revealed the United States and China as leading contributors in this research domain. The field has progressively transitioned from fundamental mechanistic investigations to clinical applications, particularly focusing on drug resistance mechanisms, and combination therapy. LONP1 was identified as a critical mitochondrial regulator strongly associated with prostate cancer progression. Our AI-designed antibody (Antibody_82) demonstrated superior binding affinity and stability through effective targeting of LONP1s ATP-binding site. ConclusionThis bibliometric study delineates evolving research trends in mitochondrial involvement in prostate cancer. The developed LONP1-targeting antibody shows promising therapeutic potential for castration-resistant prostate cancer (CRPC) patients, potentially offering more effective treatment alternatives.